CONMED (NYSE:CNMD) Reaches New 12-Month Low – Here’s What Happened

CONMED Corporation (NYSE:CNMD)’s share price hit a new 52-week low during trading on Thursday . The company traded as low as $36.30 and last traded at $36.78, with a volume of 312542 shares traded. The stock had previously closed at $38.69.

More CONMED News

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q4 results beat analysts: CONMED reported $1.43 EPS (vs. $1.32 est.) and $373.2M revenue (vs. $366.9M est.), with revenue up ~7.9% year-over-year — this is the primary catalyst cited for the stock lift. Conmed: Q4 Earnings Snapshot
• Positive Sentiment: Gross-margin and surgical/orthopedic strength highlighted: coverage notes improved gross margin and outperformance in ortho/surgical segments drove the beat and underpin management’s 2026 outlook. CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up
• Positive Sentiment: Analyst note: Wells Fargo nudged its price target up to $42 (equal-weight), signaling modest upside from current levels and validating the quarter’s credibility. Benzinga
• Positive Sentiment: Management commentary and outlook: call highlights and deep-dive pieces emphasize strategic refocusing and ortho momentum setting the tone for 2026 expectations. CNMD Q4 Deep Dive: Ortho Outperformance and Strategic Refocusing Shape 2026 Outlook
• Neutral Sentiment: Earnings call transcripts and coverage are widely available for deeper read — useful for investors wanting management detail and segment-level commentary. Earnings Call Transcript
• Neutral Sentiment: Street posture mixed: Needham reaffirmed a Hold rating, indicating some analysts remain cautious despite the beat. Benzinga
• Neutral Sentiment: Analyst models: sell-side consensus still implies moderate 2026 earnings (consensus ~4.35 EPS), so follow-through depends on sustained ortho/surgical momentum and margin trends. Compared to Estimates, Conmed (CNMD) Q4 Earnings: A Look at Key Metrics
• Negative Sentiment: Technical/valuation headwinds remain: the stock still trades well below its 52‑week high and under longer-term moving averages, so multiple expansion may be limited absent sustained execution.

Analysts Set New Price Targets

A number of analysts have issued reports on CNMD shares. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CONMED in a research note on Wednesday, January 21st. Zacks Research lowered shares of CONMED from a “hold” rating to a “strong sell” rating in a report on Thursday, January 1st. JPMorgan Chase & Co. reduced their target price on shares of CONMED from $58.00 to $52.00 and set a “neutral” rating on the stock in a research note on Thursday, November 6th. Needham & Company LLC reiterated a “hold” rating on shares of CONMED in a report on Thursday. Finally, Piper Sandler cut their price target on shares of CONMED from $68.00 to $55.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $52.83.

CONMED Trading Up 2.7%

The company’s 50 day simple moving average is $41.33 and its two-hundred day simple moving average is $46.35. The company has a market cap of $1.19 billion, a PE ratio of 25.36, a price-to-earnings-growth ratio of 1.66 and a beta of 0.96. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.10 and a quick ratio of 0.95.

CONMED (NYSE:CNMD) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $1.43 EPS for the quarter, topping the consensus estimate of $1.32 by $0.11. CONMED had a net margin of 3.42% and a return on equity of 14.36%. The firm had revenue of $373.20 million for the quarter, compared to analyst estimates of $366.88 million. During the same period in the prior year, the business posted $1.34 EPS. The business’s revenue for the quarter was up 7.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that CONMED Corporation will post 4.35 EPS for the current fiscal year.

Hedge Funds Weigh In On CONMED

Several hedge funds have recently bought and sold shares of CNMD. AQR Capital Management LLC lifted its position in shares of CONMED by 19.9% during the first quarter. AQR Capital Management LLC now owns 14,199 shares of the company’s stock worth $857,000 after purchasing an additional 2,357 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in CONMED by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,354 shares of the company’s stock worth $1,108,000 after buying an additional 800 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in CONMED by 5.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 82,686 shares of the company’s stock worth $4,993,000 after buying an additional 4,565 shares in the last quarter. Intech Investment Management LLC boosted its position in CONMED by 34.6% in the 1st quarter. Intech Investment Management LLC now owns 22,505 shares of the company’s stock valued at $1,359,000 after buying an additional 5,780 shares during the period. Finally, GAMMA Investing LLC boosted its position in CONMED by 17.1% in the 2nd quarter. GAMMA Investing LLC now owns 1,542 shares of the company’s stock valued at $80,000 after buying an additional 225 shares during the period.

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.